2018 | 2017 | 2016 | 2015 | 2014
01/08/18Chiasma Reports on Significant Progress Made During 2017
Initiated CHIASMA OPTIMAL Phase 3 Clinical Trial after SPA agreement with FDA Announces expected year-end 2017 cash and investments balance of approximately $67 million Continues to expect existing cash and investments to be sufficient to fund operations through anticipated release of top-line data from CHIASMA OPTIMAL Phase 3 Clinical Trial by the end of 2019 WALTHAM, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company fo... 
Printer Friendly Version

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent filings with the U.S. Securities and Exchange Commission.